Compare Ascendis Pharma A/S (ASND) vs Honeywell International Inc (HON) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Honeywell International Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Honeywell International Inc trades at $225.96 (market cap $71.74B). The key difference: Honeywell International Inc is far larger — about 4× Ascendis Pharma A/S's market cap, and Honeywell International Inc pays a 4.2% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | HON | |
|---|---|---|
Market Cap | $17.74B | $71.74B |
Sector | Health | Industrials |
52-Week High | $277.18 | $248.04 |
52-Week Low | $163.32 | $188.14 |
Enterprise Value | $18.11B | $96.08B |
Dividend Yield | — | 4.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Honeywell International (HON) trades at $226.42, up 1.34% with neutral technical signals. The company maintains strong profitability with 10.89% net margin and 26.41% ROE, though revenue declined slightly to $37.44B in 2025. Recent corporate actions include a 2:1 reverse stock split and dividend payment, while analyst consensus remains bullish with a $402.40 price target. Technical indicators show mixed signals with RSI neutral and ADX suggesting bullish momentum.
HON presents a compelling investment case with strong fundamentals and analyst support, though near-term risks include declining profit margins and increased debt levels. The stock's current valuation at 18.08 P/E appears reasonable given growth prospects in automation and defense sectors, but investors should monitor execution of post-spinoff strategy and macroeconomic headwinds affecting industrial demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →
